Abstract 1682P
Background
Prostate cancer (PC) presents a significant health challenge in Africa, especially in regions like Nigeria with limited access to care. Despite medical advancements, PC treatment affects patients beyond their physical health, impacting their quality of life (QoL) and financial toxicity (FT) due to high treatment costs and inadequate insurance coverage. Patient-reported outcomes are often overlooked in African PC research, creating knowledge gaps that need to be addressed.
Methods
This descriptive cross-sectional study aimed to assess patient-reported outcomes among male PC patients at Lagos University Teaching Hospital (LUTH) and the NSIA-LUTH Cancer Centre (NLCC). Data collection involved interviewer-based structured questionnaires that inculcated QoL (FACT-P), psychosocial distress (PHQ-4), and FT (FACIT-COST). Analysis was done with RStudio, with a P-value set at <0.05 for statistical significance. Ethical approval was obtained.
Results
This study examined 200 prostate cancer patients at LUTH. Participants were primarily aged 61–70; most are married with tertiary education, and the majority are retired. Comorbidities, particularly hypertension (32.0%) and diabetes mellitus (22.5%), are prevalent. Notable findings include the impact of age, employment status, and comorbidities on QoL and FT. ECOG scores, cancer stage, and comorbidities significantly influence psychological distress levels. Associations between QoL, financial toxicity, and psychosocial distress underscore the complex interplay between these factors. No significant link was found between QoL and FT.
Conclusions
This study sheds light on the challenges faced by PC patients at LUTH, highlighting the complex interplay of factors. Economic challenges included limited health insurance coverage and financial strain. Early detection and intervention are crucial, given the distribution of cancer stages and the prevalence of comorbidities among patients. FT emerges as a significant issue, impacting patients' QoL and psychosocial well-being. The lack of significant associations with health insurance coverage suggests the need for comprehensive healthcare reforms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. O. Jimoh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11